Fisher & Paykel Healthcare (ASX:FPH, NZE:FPH) said the 10% US tariffs on products manufactured in New Zealand will not significantly impact its fiscal 2025 net profit but are expected to drive higher costs in fiscal 2026, according to a Thursday filing with the Australian and New Zealand bourses.
About 55% of its production is based in New Zealand, with around 40% of its US volumes supplied from there, the filing added, the filing said.
Shares of the company fell almost 5% in New Zealand in recent Thursday trade.